Vor bio announces $175 million private placement

Cambridge, mass., june 25, 2025 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the “pipe”) that is expected to result in gross proceeds of approximately $175 million, before deducting expenses.
VOR Ratings Summary
VOR Quant Ranking